You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

261 Results
Guidelines and Advice
Status: Current
Mar 2019
Guidelines and Advice
Status: Current
ID: GL 5-3ORG
Version: 2
Apr 2019
Cancer facts
May 2019
Guidelines and Advice
Status: Current
ID: ES SCT-10
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
ixazomib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer facts
Jun 2019
Guidelines and Advice
Status: In-Review
ID: GL 2-24
May 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
DOXOrubicin,
vinCRIStine,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Guidelines and Advice
Status: Current
ID: GL 12-10
Version: 2
Jul 2019
Guidelines and Advice
Status: Current
ID: PET 2018-2
Jul 2019
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023

Pages